Christopher Sabine Douglas Almond, MD
Pediatric Cardiology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Office
- 1
Offices
1 location
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Almond’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C128501 · Current
Licensed to practise in California · since 2014 · expires 2027-04-30 · University of Connecticut School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$2,368 in 2023
Medicaid paid $2,368 for 33 billed services this clinician did in 2023, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 33 | $2,368 |
| 2023 | 33 | 1 | 13 | $2,368 |
Drugs they prescribed that Part D paid
$127
Pharmacies billed $127 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 21) in 2024. Too few prescriptions to compare fairly with other clinicians.
21 generic and 0 brand-name prescriptions · $127 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Warfarin | 20 | $51 | $3 |
Year by year
| 2024 | 21 | None | 0% (0) | 0% | $127 |
| 2023 | 22 | None | 0% (0) | 0% | $497 |
| 2021 | 16 | None | 0% (0) | 0% | $166 |
| 2020 | 13 | None | 0% (0) | 0% | $92 |
| 2019 | 17 | None | 0% (0) | 0% | $226 |
| 2018 | 26 | None | 0% (0) | 0% | $131 |
| 2017 | 27 | None | 0% (0) | None | $135 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Warfarin | 21 | $389 | $19 |
2021: 1 drug
| Warfarin | 16 | $166 | $10 |
2020: 1 drug
| Warfarin | 13 | $92 | $7 |
2019: 1 drug
| Warfarin | 16 | $117 | $7 |
2018: 1 drug
| Warfarin | 26 | $131 | $5 |
2017: 1 drug
| Warfarin | 24 | $109 | $5 |
Money from drug and device companies
$2,111 in 2025
| 2025 | 1 | 9 | None | $2,111 |
| 2024 | 1 | 1 | None | $30 |
| 2023 | 2 | 20 | None | $10,931 |
| 2020 | 1 | 2 | None | $158 |
| 2019 | 1 | 15 | None | $1,251 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | None | $2,111 | 9 payments
|
See all 9 published payments
| Merck Sharp & Dohme | Meals · 2025-04-26 | None | $50 |
| Merck Sharp & Dohme | Travel · 2025-04-26 | None | $413 |
| Merck Sharp & Dohme | Meals · 2025-04-26 | None | $64 |
| Merck Sharp & Dohme | Meals · 2025-04-26 | None | $30 |
| Merck Sharp & Dohme | Meals · 2025-04-26 | None | $50 |
| Merck Sharp & Dohme | Meals · 2025-04-25 | None | $147 |
| Merck Sharp & Dohme | Travel · 2025-04-25 | None | $745 |
| Merck Sharp & Dohme | Travel · 2025-04-25 | None | $198 |
| Merck Sharp & Dohme | Travel · 2025-04-25 | None | $413 |
See earlier years (2024, 2023, 2020, 2019)
2024: $30
| Merck Sharp & Dohme | Verquvo | $30 | 1 payment
|
2023: $10,931
| Merck Sharp & Dohme | Verquvo | $10,746 | 15 payments
|
| Getinge USA Sales | Cardiohelp | $185 | 5 payments
|
2020: $158
| Abbott Laboratories | Cardiomems Hf System | $158 | 2 payments
|
2019: $1,251
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $1,251 | 15 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Randomized Open Label Active Controlled Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of A Venous Thromboembolic Event · 2019 | Their institution | $7,147 |
| Masimo Corporation · Almond/Stanford University/Prospective Clinical Study To Evaluate the Accuracy of Pulse Oximeters in Children With Darker Skin Pigmentation · 2024 | Their institution | $4,343 |
| PFIZER INC. · A Randomized Open Label Active Controlled Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of A Venous Thromboembolic Event · 2023 | This clinician | $3,228 |
| PFIZER INC. · A Randomized Open Label Active Controlled Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of A Venous Thromboembolic Event · 2020 | Their institution | $567 |
Professional record
- NPI
- 1326000324
- Licence
- CA C128501, MA 210994California C128501: Current · expires 2027-04-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0202X (2080P0202X); Pediatrics (208000000X); Federal specialty code 2080P0203X (2080P0203X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2006-04-05
- NPI last updated
- 2024-04-11
- NPI record certified
- 2024-04-11
This is when the NPI record was last certified, not a medical board exam.